trending Market Intelligence /marketintelligence/en/news-insights/trending/SD6Gk_8OeBW0-oamuEqcGA2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Innovus Pharmaceuticals plans common stock offering


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

Innovus Pharmaceuticals plans common stock offering

Innovus Pharmaceuticals Inc. plans to sell common stock and warrants in an underwritten public offering.

The company intends to use the net proceeds from the offering for the commercial launch of allergic rhinitis treatment FlutiCare, working capital and general corporate purposes, including sales and marketing activities, product development and capital expenditures.

H.C. Wainwright & Co. LLC is acting as the exclusive placement agent for the offering.